NCT04892342View on ClinicalTrials.gov

Study of ESG401 in Adults With Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Neoplasms, BreastNeoplasms, LungNeoplasms,ColorectalNeoplasms, BladderNeoplasm of StomachNeoplasms,Ovarian
Interventions
DRUG

ESG401

Administered via intravenous (IV) infusion

Trial Locations (3)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

300060

Tianjin Medical University Cancer Institute & Hospital, Tianjin

310003

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Shanghai Escugen Biotechnology Co., Ltd

INDUSTRY

NCT04892342 - Study of ESG401 in Adults With Solid Tumors | Biotech Hunter | Biotech Hunter